Startups
Deerfield Management-backed Jaguar Gene Therapy, and its ciliopathy-focused subsidiary Axovia Therapeutics, launched today with an undisclosed Series A.
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.
Life sciences companies across the globe are raking in investment dollars to advance drug programs.
The launch of Fore Biotherapeutics in the U.S. reflects an evolved biotech business model focused on matching patients with unaddressed tumor mutations with the right oncology medicines in the clinic, the company said.
The new company, FS Development II, announced this week it raised $175 million in an upsized offering at $10 per share. The shares will be listed on the Nasdaq under the ticker symbol FSII.
The company announced this morning it is merging with special purpose acquisition company Alpha Healthcare Acquisition Corp. and will begin trading on the Nasdaq exchange under the ticker symbol “HUMA” in the second quarter of 2021.
Centessa Pharmaceuticals, based in Cambridge, Massachusetts and London, launched what it is calling a “novel asset-centric pharmaceutical company.”
As part of the Takeda deal, Ensoma will do preclinical research for therapies in up to five rare disease indications, and both companies will work on Investigational New Drug-enabling studies.
Immunai today announced it has received $60 million in Series A funding, bringing its total funding since inception in December 2018 to $80 million.
There have been a few life sciences companies that have been attracting attention this week with strong Series A rounds.
PRESS RELEASES